Resverlogix To Host Research & Development Update Featuring Key Opinion Leaders in Cardiovascular and Renal Disease

CALGARY, Oct. 4, 2016 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) will host R&D update events in New York, NY and London, UK, featuring presentations from two internationally recognized key opinion leaders.

New York Event Details:


Thursday, October 13, 2016


12:00 – 14:15 EDT


The Yale Club of NYC, Roof Top Restaurant

22nd Floor, 50 Vanderbilt Avenue at 44th St

Webcast Link:


Presentations will be available on the Company's website immediately prior to the start of the event at: An archived replay of the webcast will also be available on the Company website by clicking on this link.

London Event Details:


Monday, October 17, 2016


12:00 – 14:15 BST


Innholders Hall

30 College Street


Featured key opinion leaders presenting at both events:

Professor Kausik Ray, MBCHB, MD, MPHIL, FACC, FAHA, FESC, FRCP. Professor of Public Health, Department of Primary Care and Public Health, School of Public Health, Imperial College London, UK. Chairman, Resverlogix BETonMACE Clinical Steering Committee.

Dr. Kamyar Kalantar-Zadeh, MD, MPH, PhD. Professor of Medicine, Epidemiology, Pediatrics and Public Health, University of California, Irvine School of Medicine. Chairman, Resverlogix Renal Clinical Advisory Board.

Resverlogix senior management presenters will include:

Mr. Donald J. McCaffrey, President and Chief Executive Officer
Dr. Ewelina Kulikowski, Ph.D., Senior Vice President of Research & Development
Dr. Michael Sweeney, M.D., Senior Vice President of Clinical Development

Only registered guests that have RSVP'd in advance will be permitted to attend the event.

To RSVP, please send an email to:

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on Twitter: @Resverlogix_RVX (, or on our blog at

SOURCE Resverlogix Corp.

For further information: Investor Relations, Email:, Phone: 403-254-9252, Web:


Organization Profile

Resverlogix Corp.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890